ALB and non-small cell lung carcinoma: Our previous research demonstrated sintilimab’s safety and efficacy in a well-defined subgroup of NSCLC patients (20), identifying clinical stage, treatment lines, LIPI score, and ALB levels as significant predictors of OS.